

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
9 June 2005 (09.06.2005)

PCT

(10) International Publication Number
WO 2005/051453 A1

(51) International Patent Classification⁷: A61L 31/10, 31/16, 27/34, 27/54 (72) Inventors; and
(75) Inventors/Applicants (for US only): HOSSAINY, Syed, F.A. [US/US]; 34325 Tupelo Street, Fremont, California 94555 (US). TANG, Yiwen [US/US]; 1230 San Tomas Aquino Road, No. 223, San Jose, California 95117 (US).

(21) International Application Number: PCT/US2004/038135 (22) International Filing Date: 15 November 2004 (15.11.2004) (24) Agents: WININGER, Aaron et al.; Squire, Sanders & Dempsey L.L.P., 600 Hansen Way, Palo Alto, California 94304-1043 (US).

(25) Filing Language: English (26) Publication Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(30) Priority Data: 10/718,278 19 November 2003 (19.11.2003) US (71) Applicant (for all designated States except US): ADVANCED CARDIOVASCULAR SYSTEMS, INC. [US/US]; 3200 Lakeside Drive, Santa Clara, California 95054 (US).

[Continued on next page]

(54) Title: BIOLOGICALLY BENEFICIAL COATINGS FOR IMPLANTABLE DEVICES CONTAINING FLUORINATED POLYMERS AND METHODS FOR FABRICATING THE SAME



(57) Abstract: Coatings for an implantable medical device and a method of fabricating the coatings are disclosed. The coatings comprise a fluorinated polymer and a biologically beneficial polymer, an example of which includes poly(ethylene-glycol)-block poly (butylene terephthalate)-block-poly(ethylene-glycol). A biologically active agent can be additionally conjugated to the biologically beneficial polymer.



(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *with international search report*

BIOLOGICALLY BENEFICIAL COATINGS FOR IMPLANTABLE DEVICES CONTAINING
FLUORINATED POLYMERS AND METHODS FOR FABRICATING THE SAME

BACKGROUND OF THE INVENTION

5 1. Field of the Invention

This invention is directed to coatings for drug delivery devices, such as drug eluting vascular stents, and methods for producing the same.

2. Description of the State of the Art

Percutaneous transluminal coronary angioplasty (PTCA) is a procedure for treating heart 10 disease. A catheter assembly having a balloon portion is introduced percutaneously into the cardiovascular system of a patient via the brachial or femoral artery. The catheter assembly is advanced through the coronary vasculature until the balloon portion is positioned across the occlusive lesion. Once in position across the lesion, the balloon is inflated to a predetermined size to radially compress against the atherosclerotic plaque of the lesion to remodel the lumen wall. 15 The balloon is then deflated to a smaller profile to allow the catheter to be withdrawn from the patient's vasculature.

A problem associated with the above procedure includes formation of intimal flaps or torn arterial linings which can collapse and occlude the conduit after the balloon is deflated.

Moreover, thrombosis and restenosis of the artery may develop over several months after the 20 procedure, which may require another angioplasty procedure or a surgical by-pass operation. To reduce the partial or total occlusion of the artery by the collapse of arterial lining and to reduce the chance of the development of thrombosis and restenosis, a stent is implanted in the lumen to maintain the vascular patency.

Stents are used not only as a mechanical intervention but also as a vehicle for providing 25 biological therapy. As a mechanical intervention, stents act as scaffoldings, functioning to physically hold open and, if desired, to expand the wall of the passageway. Typically, stents are capable of being compressed, so that they can be inserted through small vessels via catheters, and then expanded to a larger diameter once they are at the desired location. Examples in patent literature disclosing stents which have been applied in PTCA procedures include stents illustrated

in U.S. Patent No. 4,733,665 issued to Palmaz, U.S. Patent No. 4,800,882 issued to Gianturco, and U.S. Patent No. 4,886,062 issued to Wiktor.

5 Biological therapy can be achieved by medicating the stents. Medicated stents provide for the local administration of a therapeutic substance at the diseased site. In order to provide an efficacious concentration to the treated site, systemic administration of such medication often produces adverse or toxic side effects for the patient. Local delivery is a preferred method of treatment in that smaller total levels of medication are administered in comparison to systemic dosages, but are concentrated at a specific site. Local delivery thus produces fewer side effects and achieves more favorable results. One proposed method for medicating stents involves the use 10 of a polymeric carrier coated onto the surface of a stent. A solution which includes a solvent, a polymer dissolved in the solvent, and a therapeutic substance dispersed in the blend is applied to the stent. The solvent is allowed to evaporate, leaving on the stent surface a coating of the polymer and the therapeutic substance impregnated in the polymer.

15 Local administration of therapeutic agents via stents has shown some favorable results in reducing restenosis. However, there is a great need for better coatings for the effective management of restenosis. Embodiments of the present invention disclose stent coatings having improved properties, both physical and biological.

BRIEF DESCRIPTION OF THE DRAWINGS

20 FIGs. 1A, 1B, and 1C show the microphotographs demonstrating overall views of the outer surface of the stent coated according to an embodiment of the present invention after the simulated *in vitro* testing.

FIGs. 2A, 2B, and 2C show the microphotographs demonstrating overall views of the inner surface of the stent coated according to an embodiment of the present invention after the simulated *in vitro* testing.

25

SUMMARY

30 A medical article is provided, the article comprising a coating disposed on at least a portion of an implantable medical device, the coating comprising a fluorinated polymer, and a biologically beneficial polymer. Fluorinated polymers that can be used include products of polymerization of fluorinated olefins or mixtures thereof, products of polymerization of

fluorinated cyclic esters, fluorine-containing cyclic polymers having a main chain with an asymmetrical cyclic structure, and copolymers of perfluoro-2,2-dimethyl-1,3-dioxole with perfluoroolefins or with perfluoro(alkyl vinyl) ethers. One example of a fluorinated polymer that can be used is poly(vinylidene fluoride-co-hexafluoropropene) available under the trade name 5 SOLEF. Examples of biologically beneficial polymers that can be used include poly(ethylene-glycol), poly(ethylene-glycol)-block-poly(butylene terephthalate)-block-poly(ethylene-glycol) (available under the trade name POLYACTIVE), poly(butylene terephthalate)-block- poly(ethylene-glycol)-block poly(butylene terephthalate), hyaluronic acid or derivatives thereof, phosphoryl choline, polyaspirin, and poly(ester amides). Biologically beneficial polymers can be 10 optionally modified using biologically active agents such as peptides, antisense agents, rapamycin and structural derivatives or functional analogs thereof, and molecules that are sources of nitrogen oxide.

A method for fabricating a medical article is provided, the method comprises depositing a fluorinated polymer on at least a portion of an implantable medical device to form a first 15 polymeric layer, and depositing a biologically beneficial polymer on at least a portion of the first polymeric layer to form a second polymeric layer.

DETAILED DESCRIPTION

1. Terms and Definitions

20 The following terms apply:

The term "biologically beneficial" refers to a product that brings about biological benefits to a patient including both therapeutic and preventative effects.

The terms "biologically degradable" or "biodegradable" refer to coatings and/or polymers that are capable of being degraded, dissolved, and/or eroded when exposed to bodily fluids such 25 as blood and are gradually resorbed, absorbed and/or eliminated by the body. The processes of breaking down and eventual absorption and elimination of the coating and/or polymer can be caused, for example, by hydrolysis, metabolic processes, bulk or surface erosion, and the like. It is understood that after the process of degradation, dissolution, and/or erosion, has been completed, a very small to zero amount of coating or polymer will remain on the stent. Whenever 30 the terms "degradable," "biodegradable," or "biologically degradable" are used in this application,

they are intended to broadly include biologically degradable, biologically erodable, bioabsorbable, and bioresorbable coatings and/or polymers.

5 The term "block copolymer" is defined in accordance with the terminology used by the International Union of Pure and Applied Chemistry (IUPAC). According to the IUPAC, "block copolymer" refers to a copolymer containing a linear arrangement of blocks. The block is defined as a portion of a polymer molecule in which the monomeric units have at least one constitutional or configurational feature absent from the adjacent portions.

The term "fluorinated polymer" is defined as a polymer having at least one atom of fluorine in at least one constituent unit of the polymer.

10 The term "highly fluorinated polymer" is defined as any homopolymer, copolymer, terpolymer or a blend thereof in which at least 50% of monovalent atoms in the macromolecule are fluorine atoms.


The term "polymers based on fluorinated olefins" refers to the polymers which include units derived from fully or partially fluorinated olefins, such as fluorinated ethylene.

15 The term "non-fouling" is defined as ability of a chemical compound, such as a polymer, to delay, prevent or at least reduce a build-up of a denatured layer of protein on the stent surface or on the stent coating.

The term "conjugated" is defined as "linked," for example, covalently linked. The term "conjugating" is defined as a process of forming a link, for example, a covalent link.

20 The term "polymer-analogous transformation" is defined as a synthetic process of replacing functional groups in a macromolecule of the original polymer with other functional groups thus making a new polymer having new properties. The new polymer, however, retains many features of the original polymer, such as the original degree of polymerization and the structure of the backbone of the original polymer (including linear or branched nature) after the 25 process of polymer-analogous transformation is completed.

The term "poly(ester amide)" is defined as a polymer having at least one ester fragment (I) and at least one amide fragment (II):



2. Embodiments of the Invention

A coating for an implantable medical device, such as a stent, according to embodiments of the present invention, can be a multi-layer structure that can include at least one of the following layers:

5 (a) a drug-polymer layer (also referred to as "reservoir" or "reservoir layer") or alternatively a polymer free drug layer;

(b) a primer layer;

(c) a topcoat layer; and/or

(d) a finishing coat layer.

10 Each layer of the stent coating can be formed on the stent by dissolving a polymer or a blend of polymers in a solvent, or a mixture of solvents, and applying the resulting polymer solution on the stent by spraying or immersing the stent in the solution. After the solution has been applied onto the stent, the coating is dried by allowing the solvent to evaporate. The process of drying can be accelerated if the drying is conducted at an elevated temperature. For example, 15 the coating can be baked, at a temperature such as 55°C to 80°C.

20 To incorporate a drug into the reservoir layer, the drug in a form of a solution can be combined with the polymer solution that is applied onto the stent. Alternatively, to fabricate a polymer free drug layer, the drug can be dissolved in a suitable solvent or mixture of solvents, and the resulting drug solution can be applied on the stent by spraying or immersing the stent in the drug solution.

Instead of introducing the drug in a solution, the drug can be introduced as a colloid system, such as a suspension in an appropriate solvent phase. To make the suspension, the drug can be dispersed in the solvent phase using conventional techniques used in colloid chemistry. Depending on a variety of factors, e.g., the nature of the drug, those having ordinary skill in the 25 art can select the suitable solvent to form the solvent phase of the suspension, as well as the quantity of the drug to be dispersed in the solvent phase. The suspension can be mixed with a polymer solution and the mixture can be applied on the stent as described above. Alternatively, the drug suspension can be applied on the stent without being mixed with the polymer solution.

The drug-polymer layer can be applied directly onto at least a part of the stent surface to serve as a reservoir for at least one active agent or a drug which is incorporated into the reservoir layer. The optional primer layer can be applied between the stent and the reservoir to improve the adhesion of the drug-polymer layer to the stent. The topcoat layer can be applied over at least a portion of the reservoir layer and serves as a rate limiting membrane which helps to control the rate of release of the drug. The topcoat layer can be essentially free from any active agents or drugs. The optional finishing coat layer can be applied over at least a portion of the topcoat layer to form the outermost layer of the stent coating to further control the rate of release of the drug. If the finishing coat layer is not used, the topcoat layer is the outermost layer of the stent coating.

10 The outermost layer of the stent coating can serve to provide the stent coating with biologically beneficial and/or non-fouling properties. To form the outermost layer having biologically beneficial and/or non-fouling properties, a biologically beneficial polymer can be included in the outermost layer, as discussed below in more detail. Optionally, any or all of the remaining layers of the stent coating can be also include a biologically beneficial polymer. In 15 some embodiments of the invention, additional biological benefits can be imparted to the outermost layer of the stent coating. To provide the additional biological benefits, at least one biologically active agent can be incorporated into the outermost layer of the stent coating, for example, by conjugating the biologically active agent to the biologically beneficial polymer that is present in the outermost layer.


20 To illustrate in more detail, in the stent coating having all four layers described above (i.e., the primer, the reservoir layer, the topcoat layer, and the finishing coat layer), the outermost layer is the finishing coat layer, which can include a biologically beneficial polymer and, optionally, an additional biologically active agent conjugated to the biologically beneficial polymer. In this case, optionally, the remaining layers (i.e., the primer, the reservoir and the topcoat layers) can also 25 include a biologically beneficial polymer, which can be the same or different in each of the four layers.

30 If the finishing coat layer is not used, the stent coating can have, for example, only three layers (i.e., the optional primer, the reservoir, and the topcoat layers). The topcoat layer in this case is the outermost layer of the stent coating, which can include a biologically beneficial polymer and, optionally, an additional biologically active agent conjugated to the biologically beneficial polymer. Optionally, the primer and/or the reservoir layers can also include a biologically beneficial polymer, which can be the same or different in each of the three layers.

The polymers that can be included in the reservoir, topcoat, and/or the finishing coat layers of the stent coating are as follows.

A. The Fluorinated Layer of the Stent Coating

The stent coating, for example, the reservoir layer, can include a fluorinated polymer, for 5 example a highly fluorinated polymer defined above. One example of a highly fluorinated polymer that can be used includes poly(vinylidene fluoride-co-hexafluoropropene) (PVDF-HFP) having a general formula (III):



10

Various brands of PVDF-HFP known as SOLEF family of products, available from Solvay Fluoropolymers, Inc. of Houston, Texas, can be used, for example, SOLEF 21508 having about 85 mass % of vinylidene fluoride-derived units and about 15 mass % of hexafluoro propene-derived units. PVDF-HFP is also available from Atofina Chemicals of Philadelphia, 15 Pennsylvania, under the trade name KYNAR.

Other highly fluorinated polymers that can be used include polymers based on fluorinated olefins or mixtures thereof. Examples of some polymers belonging to this group are provided in Table 1.

Table 1. Examples of Olefin-Based Fluorinated Polymers Suitable for Stent Coatings.

No.	Fluorinated Polymer	Abbreviation	General Formula
1	Poly(tetrafluoroethylene) ^{*)}	PTFE	$-\text{[CF}_2\text{--CF}_2\text{]}_m\text{--}$
2	Fluorinated poly(ethylene-co-propylene)	FPEP	$-\text{[CF}_2\text{--CHF}]\text{--[CH}_2\text{--CH}]\text{--}\underset{\text{CF}_3}{\underset{ }{\text{CF}}}\text{--}$
3	Poly(hexafluoropropene)	PHFP	$-\text{[CF}_2\text{--CF}]\text{--}\underset{\text{CF}_3}{\underset{ }{\text{CF}}}\text{--}$
4	Poly(chlorotrifluoroethylene)	PCTFE	$-\text{[CClF--CF}_2\text{]}_m\text{--}$
5	Poly(vinylidene fluoride) ^{**)}	PVDF	$-\text{[CF}_2\text{--CH}_2\text{]}_m\text{--}$
6	Poly(vinylidene fluoride-co-tetrafluoroethylene)	PVDF-TFE	$-\text{[CF}_2\text{--CH}_2\text{]}_m\text{--[CF}_2\text{--CF}_2\text{]}_n\text{--}$
7	Poly(vinylidene fluoride-co-hexafluoropropene)	PVDF-HFP	$-\text{[CF}_2\text{--CH}_2\text{]}_m\text{--[CF}_2\text{--CF}]\text{--}\underset{\text{CF}_3}{\underset{ }{\text{CF}}}\text{--}$
8	Poly(tetrafluoroethylene-co-hexafluoropropene)	PTFE-HFP	$-\text{[CF}_2\text{--CF}_2\text{]}_m\text{--[CF}_2\text{--CF}]\text{--}\underset{\text{CF}_3}{\underset{ }{\text{CF}}}\text{--}$

9	Poly(tetrafluoroethylene-co-vinyl alcohol)	PTFE-VAL	$-\left[CF_2-CF_2\right]_m-\left[CH_2-CH\right]_n-$ OH
10	Poly(tetrafluoroethylene-co-vinyl acetate)	PTFE-VAC	$-\left[CF_2-CF_2\right]_m-\left[CH_2-CH\right]_n-$ OC(O)CH ₃
11	Poly(tetrafluoroethylene-co-propene)	PTFEP	$-\left[CF_2-CF_2\right]_m-\left[CH_2-CH\right]_n-$ CH ₃
12	Poly(hexafluoropropene-co-vinyl alcohol)	PHFP-VAL	$-\left[CF_2-CF\right]_n-\left[CH_2-CH\right]_n-$ CF ₃ OH
13	Poly(ethylene-co- tetrafluoroethylene)	PETFE	$-\left[CH_2-CH_2\right]_m-\left[CF_2-CF_2\right]_n-$
14	Poly(ethylene-co-hexafluoropropene)	PEHFP	$-\left[CH_2-CH_2\right]_m-\left[CF_2-CF\right]_n-$ CF ₃
15	Poly(vinylidene fluoride-co-chlorotrifluoroethylene)	PVDF-CTFE	$-\left[CF_2-CH_2\right]_m-\left[CClF-CF_2\right]_n-$

^{*)} Including various brands of TEFLON available from E.I. DuPont de Nemours & Co. of

Wilmington, Delaware.

^{**) The formula shows an example of one possible FPEP. Other kinds of FPEP can be used.}

^{***) Including various brands of KYNAR.}

5 Other highly fluorinated polymers that can be used also include polymers having heterocyclic fragments or having oxygen atoms in the backbone. These classes of polymers are not based on fluorinated olefins. Examples of such polymers include:

(1) amorphous products of polymerization of fluorinated cyclic esters, such as poly(perhalo-2,2-di-loweralkyl-1,3-dioxole-co-perfluoro-2-methylene-methyl-1,3-dioxolane)

10 (designated for the purposes of this invention as "polyfluorooxalanes"), for example, poly(perhalo-2,2-dimethyl-1,3-dioxole-co-perfluoro-2-methylene-methyl-1,3-dioxolane);

(2) thermoplastic resinous fluorine-containing cyclic polymers having a main chain with an asymmetrical cyclic structure, with repeating units of cyclically polymerized perfluorallyl vinyl ether and/or perfluorobutenyl vinyl ether, e.g., poly(perfluorobutenyl vinyl ether) (PPBVE);

15 and

(3) copolymers of perfluoro-2,2-dimethyl-1,3-dioxole (PDD) with such monomers as perfluoroolefins and perfluoro(alkyl vinyl) ethers (designated for the purposes of this invention as "polyfluorooxoles"), including the TEFLON AF product. TEFLON AF is a trade name of a

product which includes poly(tetrafluoroethylene-co-perfluoro-2,2-dimethyl-1,3-dioxole) and which is available from E.I. DuPont de Nemours & Co.

Polyfluorooxoles can contain between about 1 and 99.5% (molar) units derived from PDD and the balance of units derived from perfluoro(butenyl vinyl ether), and can optionally contain 5 minor amounts of additional monomers, such as chlorinated or fluorinated olefins, e.g., tetrafluoroethylene or chlorotrifluoroethylene, and perfluorvinyl ethers such as perfluoropropylvinyl ether, perfluoro-3,6-dioxa-4-methyl-7-octenesulfonyl fluoride and methyl perfluoro-4,7-dioxa-5-methyl-8-nonenoate. A PPVBE brand under the trade name CYTOP, available from Asahi Glass Co. of Charlotte, North Carolina, can be used.

10 In one embodiment of the invention, a fluorinated polymer that can be used does not include any of the fluorinated polymers described above.

All fluorinated polymers used in the present invention are soluble in at least one organic solvent, or a blend of various organic solvents. Suitable solvents include fluorinated solvents, for example, fluorocarbon systems having the boiling temperature of about 60°C to about 140°C, such 15 as FLUORINERT FC-75 and various FREONs, and other fluorinated solvents, such as FLUX REMOVER AMS and NOVEC hydrofluoroether solvents.

FLUORINERT FC-75 is a trade name of perfluoro(2-butyltetrahydrofuran), a solvent which is available from Minnesota Mining and Manufacturing Corp. of Saint Paul, Minnesota. FREON is a trade name of various chlorinated fluorocarbons available from E.I. DuPont de 20 Nemours & Co.

FLUX REMOVER AMS is trade name of a solvent manufactured by Tech Spray, Inc. of Amarillo, Texas comprising about 93.7% of a mixture of 3,3-dichloro-1,1,1,2,2-pentafluoropropane and 1,3-dichloro-1,1,2,2,3-pentafluoropropane, and a balance of methanol, with trace amounts of nitromethane. NOVEC is a trade name of a family of solvents based on 25 hydrofluoroethers available from 3M Corp. of St. Paul, Minnesota.

Other solvents can be alternatively used to dissolve the above described fluorinated polymers. Representative examples include N,N-dimethylacetamide (DMAC), N,N-dimethylformamide (DMF), dimethylsulphoxide (DMSO), acetone, cyclohexanone, methyl isobutyl ketone, methyl ethyl ketone, N-methyl pyrrolidone, and 1,4-dioxane.

30 The reservoir layer of the stent coating can contain between greater than 0 and 100 mass % of the fluorinated polymers described above, or a blend of more than 1 of such fluorinated polymers. If less than 100% of the layer is made of the fluorinated polymers, other, alternative, polymers can comprise the balance. Examples of the alternative polymers that can be used include polyacrylates, such as poly(butyl methacrylate), poly(ethyl methacrylate), and poly(ethyl

methacrylate-co-butyl methacrylate), poly(vinyl pyrrolidone), poly(hydroxyvalerate), poly(L-lactic acid), polycaprolactone, poly(lactide-co-glycolide), poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoester, polyanhydride, poly(glycolic acid), poly(D,L-lactic acid), poly(glycolic acid-co-trimethylene carbonate), polyphosphoester, 5 polyphosphoester urethane, poly(amino acids), cyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), co-poly(ether-esters), polyalkylene oxalates, polyphosphazenes, biomolecules (such as fibrin, fibrinogen, cellulose, starch, collagen, and hyaluronic acid or derivatives thereof), polyurethanes, silicones, polyesters, polyolefins, polyisobutylene and ethylene-alphaolefin copolymers, vinyl halide polymers and copolymers (such as polyvinyl chloride), polyvinyl ethers (such as polyvinyl methyl ether), polyvinylidene chloride, polyacrylonitrile, polyvinyl ketones, polyvinyl aromatics (such as polystyrene), polyvinyl esters (such as polyvinyl acetate), copolymers of vinyl monomers with each other and olefins, e.g., poly(ethylene-co-vinyl alcohol) (EVAL), ethylene-methyl methacrylate copolymers, acrylonitrile-styrene copolymers, ABS resins, and ethylene-vinyl acetate copolymers; polyamides (such as 10 Nylon 66 and polycaprolactam), alkyd resins, polycarbonates, polyoxymethylenes, polyimides, polyethers, epoxy resins, polyurethanes, rayon, rayon-triacetate, cellulose, cellulose acetate, cellulose butyrate, cellulose acetate butyrate, cellophane, cellulose nitrate, cellulose propionate, cellulose ethers, and carboxymethyl cellulose. In one embodiment, the blend can be free from 15 any of these aforementioned alternative polymers.

20 B. The Outermost Layer of the Stent Coating

As mentioned above, the outermost layer of the stent coating can include a biologically beneficial polymer. One example of a biologically beneficial polymer that can be used is poly(ethylene glycol)(PEG). PEG is a biologically beneficial polymer, reducing smooth muscle cells proliferation at the lesion site and thus capable of inhibiting restenosis. Another example of a 25 biologically beneficial polymer that can be used is a block-copolymer of PEG with poly(butylene terephthalate) (PBT), such as poly(ethylene-glycol)-block-poly(butylene terephthalate)-block-poly(ethylene-glycol)(PEG-PBT-PEG). This block-copolymer can be obtained, for example, by trans-esterification of dibutylene terephthalate with PEG.

PEG-PBT-PEG block copolymer is known under a trade name POLYACTIVE and is 30 available from IsoTis Corp. of Holland. In PEG-PBT-PEG, the ratio between the units derived from ethylene glycol and the units derived from butylene terephthalate can be between about 0.67:1 and about 9:1. The molecular weight of the units derived from ethylene glycol can be between about 300 and about 4,000 Daltons. Alternatively, if desired, the positions of the

moieties in the PEG-PBT-PEG block copolymer can be switched to obtain a BAB block copolymer, poly(butylene terephthalate)-block-poly(ethylene-glycol)-block poly(butylene terephthalate)(PBT-PEG-PBT).

Both PEG-PBT-PEG and PBT-PEG-PBT block copolymers contain fragments with ester bonds. Ester bonds are known to be water-labile bonds. When in contact with slightly alkaline blood, ester bonds are subject to catalyzed hydrolysis, thus ensuring biological degradability of the block-copolymer. One product of degradation of either PEG-PBT-PEG or PBT-PEG-PBT is expected to be PEG, which is biologically beneficial as described above. As a result, including either PEG-PBT-PEG or PBT-PEG-PBT in the outermost layer of the stent coating is expected to provide the coating with biologically beneficial properties.

In addition to PEG and POLYACTIVE polymers, other biologically beneficial polymers can be included in the outermost layer of the stent coating. Examples of such alternative biologically beneficial polymers include hyaluronic acid or derivatives thereof, poly(ethylene oxide-co-propylene oxide) phosphoryl choline, polyaspirin, and polymers of the class of poly(ester amides). One brand of poly(ethylene oxide-co-propylene oxide) that can be used is available from BASF Corp. of Parsippany, New Jersey under the trade name PLURONIC.



Poly(ester amides) are polymers having a general formula (IV):



wherein M is a moiety represented by the structure



P can include any of the following moieties (P1) – (P4):



methacrylate-co-butyl methacrylate), poly(vinyl pyrrolidone), poly(hydroxyvalerate), poly(L-lactic acid), polycaprolactone, poly(lactide-co-glycolide), poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoester, polyanhydride, poly(glycolic acid), poly(D,L-lactic acid), poly(glycolic acid-co-trimethylene carbonate), polyphosphoester, 5 polyphosphoester urethane, poly(amino acids), cyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), co-poly(ether-esters), polyalkylene oxalates, polyphosphazenes, biomolecules (such as fibrin, fibrinogen, cellulose, starch, collagen, and hyaluronic acid or derivatives thereof), polyurethanes, silicones, polyesters, polyolefins, polyisobutylene and ethylene-alphaolefin copolymers, vinyl halide polymers and copolymers (such as polyvinyl 10 chloride), polyvinyl ethers (such as polyvinyl methyl ether), polyvinylidene chloride, polyacrylonitrile, polyvinyl ketones, polyvinyl aromatics (such as polystyrene), polyvinyl esters (such as polyvinyl acetate), copolymers of vinyl monomers with each other and olefins, e.g., poly(ethylene-co-vinyl alcohol) (EVAL), ethylene-methyl methacrylate copolymers, acrylonitrile-styrene copolymers, ABS resins, and ethylene-vinyl acetate copolymers; polyamides (such as 15 Nylon 66 and polycaprolactam), alkyd resins, polycarbonates, polyoxymethylenes, polyimides, polyethers, epoxy resins, polyurethanes, rayon, rayon-triacetate, cellulose, cellulose acetate, cellulose butyrate, cellulose acetate butyrate, cellophane, cellulose nitrate, cellulose propionate, cellulose ethers, and carboxymethyl cellulose. In one embodiment, the blend can be free from any of these aforementioned alternative polymers.

20 B. The Outermost Layer of the Stent Coating

As mentioned above, the outermost layer of the stent coating can include a biologically beneficial polymer. One example of a biologically beneficial polymer that can be used is poly(ethylene glycol)(PEG). PEG is a biologically beneficial polymer, reducing smooth muscle cells proliferation at the lesion site and thus capable of inhibiting restenosis. Another example of a 25 biologically beneficial polymer that can be used is a block-copolymer of PEG with poly(butleneterephthalate) (PBT), such as poly(ethylene-glycol)-block-poly(butleneterephthalate)-block-poly(ethylene-glycol)(PEG-PBT-PEG). This block-copolymer can be obtained, for example, by trans-esterification of dibutleneterephthalate with PEG.

PEG-PBT-PEG block copolymer is known under a trade name POLYACTIVE and is 30 available from IsoTis Corp. of Holland. In PEG-PBT-PEG, the ratio between the units derived from ethylene glycol and the units derived from butylene terephthalate can be between about 0.67:1 and about 9:1. The molecular weight of the units derived from ethylene glycol can be between about 300 and about 4,000 Daltons. Alternatively, if desired, the positions of the

moieties in the PEG-PBT-PEG block copolymer can be switched to obtain a BAB block copolymer, poly(butylene terephthalate)-block-poly(ethylene-glycol)-block poly(butylene terephthalate)(PBT-PEG-PBT).

Both PEG-PBT-PEG and PBT-PEG-PBT block copolymers contain fragments with ester bonds. Ester bonds are known to be water-labile bonds. When in contact with slightly alkaline blood, ester bonds are subject to catalyzed hydrolysis, thus ensuring biological degradability of the block-copolymer. One product of degradation of either PEG-PBT-PEG or PBT-PEG-PBT is expected to be PEG, which is biologically beneficial as described above. As a result, including either PEG-PBT-PEG or PBT-PEG-PBT in the outermost layer of the stent coating is expected to provide the coating with biologically beneficial properties.

In addition to PEG and POLYACTIVE polymers, other biologically beneficial polymers can be included in the outermost layer of the stent coating. Examples of such alternative biologically beneficial polymers include hyaluronic acid or derivatives thereof, poly(ethylene oxide-co-propylene oxide) phosphoryl choline, polyaspirin, and polymers of the class of poly(ester amides). One brand of poly(ethylene oxide-co-propylene oxide) that can be used is available from BASF Corp. of Parsippany, New Jersey under the trade name PLURONIC.



Poly(ester amides) are polymers having a general formula (IV):




wherein M is a moiety represented by the structure



P can include any of the following moieties (P1) – (P4):



Q can include any of the following moieties (Q1) – (Q4):



15 R_1 can be a straight chained or branched aliphatic alkylene group C_nH_{2n} , and n can be an integer having the value between 2 and 12, e.g. ethylene, propylene, butylene, amylene (pentylene), hexylene, heptylene, octylene, nonylene, decylene, undecylene, or dodecylene group, or an aromatic group, e.g., *para*-phenylene.

20 R_2 can be hydrogen; methyl (CH_3); *iso*-propyl ($i\text{-C}_3\text{H}_7$); *sec*-butyl ($sec\text{-C}_4\text{H}_9$); *iso*-butyl ($i\text{-C}_4\text{H}_9$); or benzyl ($\text{C}_6\text{H}_5\text{-CH}_2$).


25 R_3 can be methylene (CH_2); methylmethylene (CHCH_3); *n*-propylene ($\text{CH}_2\text{CH}_2\text{CH}_2$); *iso*-propylene (CH_2CHCH_3); ethylmethylen (CHCH_2CH_3); straight chained or branched butylene, such as *n*-butylene ($\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2$), *iso*-butylene [$\text{CH}_2\text{CH}(\text{CH}_3)\text{CH}_2$], and *sec*-butylene [$\text{CH}(\text{CH}_2\text{CH}_3)\text{CH}_2$]; or *n*-amylene ($\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2$).

25 X can be a straight chained or branched aliphatic alkylene group C_nH_{2n} , and n can be an integer between 2 and 12, e.g., methylene, ethylene, propylene, butylene, amylene (pentylene), hexylene, heptylene, octylene, nonylene, decylene, undecylene, or dodecylene group.

Y can be straight chained or branched aliphatic alkylene group C_2H_4 (ethylene), C_4H_8 (butylene), or C_5H_{10} (amylene or pentylene).

30 Z can be a biologically beneficial moiety derived from PEG, poly(propylene glycol), hyaluronic acid or derivatives thereof, poly(2-hydroxyethyl methacrylate) or cellulosics; and m and n , are integers.

One example of poly(ester amide) that can be used includes products of reaction between diol-diamines and dicarboxylic acids, one unit of which is shown by the general formula (V).



wherein R can be selected from a group consisting of hydrogen; methyl, *iso*-propyl, *sec*-butyl, *iso*-butyl, or benzyl; x is an integer having a value between 2 and 12; and y is an integer having a value between 1 and 12.

The outermost layer of the stent coating can contain between greater than 0 and 100 mass 5 % of the biologically beneficial polymers described above, or a blend of more than 1 of such biologically beneficial polymers. In one embodiment of the invention, a biologically beneficial polymer that can be used does not include any of the biologically beneficial polymers described above.

If less than 100% of the layer is made of the biologically beneficial polymers, other, 10 alternative, polymers can comprise the balance. Examples of the alternative polymers that can be used include polyacrylates, such as poly(butyl methacrylate), poly(ethyl methacrylate), and poly(ethyl methacrylate-co-butyl methacrylate), and fluorinated polymers and/or copolymers, such as poly(vinylidene fluoride) and poly(vinylidene fluoride-co-hexafluoro propene), poly(vinyl pyrrolidone), poly(hydroxyvalerate), poly(L-lactic acid), polycaprolactone, poly(lactide-co-glycolide), poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate), polydioxanone, 15 polyorthoester, polyanhydride, poly(glycolic acid), poly(D,L-lactic acid), poly(glycolic acid-co-trimethylene carbonate), polyphosphoester, polyphosphoester urethane, poly(amino acids), cyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), co-poly(ether-esters), polyalkylene oxalates, polyphosphazenes, polyurethanes, silicones, polyesters, polyolefins, 20 polyisobutylene and ethylene-alphaolefin copolymers, vinyl halide polymers and copolymers (such as polyvinyl chloride), polyvinyl ethers (such as polyvinyl methyl ether), polyvinylidene chloride, polyacrylonitrile, polyvinyl ketones, polyvinyl aromatics (such as polystyrene), polyvinyl esters (such as polyvinyl acetate), copolymers of vinyl monomers with each other and olefins, e.g., poly(ethylene-co-vinyl alcohol) (EVAL), ethylene-methyl methacrylate copolymers, 25 acrylonitrile-styrene copolymers, ABS resins, and ethylene-vinyl acetate copolymers; polyamides (such as Nylon 66 and polycaprolactam), alkyd resins, polycarbonates, polyoxymethylenes, polyimides, polyethers, epoxy resins, polyurethanes, rayon, rayon-triacetate, cellulose, cellulose acetate, cellulose butyrate, cellulose acetate butyrate, cellophane, cellulose nitrate, cellulose propionate, cellulose ethers, and carboxymethyl cellulose. In one embodiment, the stent coating 30 can be free of any of these additional polymers.

The therapeutic substance which can be used in the reservoir layer can include any substance capable of exerting a therapeutic or prophylactic effect for a patient. The therapeutic substance may include small molecule substances, peptides, proteins, oligonucleotides, and the

like. The therapeutic substance could be designed, for example, to inhibit the activity of vascular smooth muscle cells. It can be directed at inhibiting abnormal or inappropriate migration and/or proliferation of smooth muscle cells to inhibit restenosis.

Examples of therapeutic substances that can be used include antiproliferative substances 5 such as actinomycin D, or derivatives and analogs thereof (manufactured by Sigma-Aldrich of Milwaukee, Wisconsin, or COSMEGEN available from Merck). Synonyms of actinomycin D include dactinomycin, actinomycin IV, actinomycin I₁, actinomycin X₁, and actinomycin C₁. The active agent can also fall under the genus of antineoplastic, anti-inflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, antiallergic and antioxidant 10 substances. Examples of such antineoplastics and/or antimitotics include paclitaxel (e.g. TAXOL® by Bristol-Myers Squibb Co., Stamford, Conn.), docetaxel (e.g. Taxotere®, from Aventis S.A., Frankfurt, Germany) methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride (e.g. Adriamycin® from Pharmacia & Upjohn, Peapack N.J.), and mitomycin (e.g. Mutamycin® from Bristol-Myers Squibb Co., Stamford, Conn.). 15 Examples of such antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vaprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, and thrombin inhibitors such as ANGIOMAX (Biogen, Inc., 20 Cambridge, Mass.). Examples of such cytostatic or antiproliferative agents include angiopeptin, angiotensin converting enzyme inhibitors such as captopril (e.g. Capoten® and Capozide® from Bristol-Myers Squibb Co., Stamford, Conn.), cilazapril or lisinopril (e.g. Prinivil® and Prinzide® from Merck & Co., Inc., Whitehouse Station, NJ); calcium channel blockers (such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine 25 antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug, brand name Mevacor® from Merck & Co., Inc., Whitehouse Station, NJ), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide. An example of 30 an antiallergic agent is permirestat potassium. Other therapeutic substances or agents which may be appropriate include alpha-interferon, genetically engineered epithelial cells, tacrolimus, dexamethasone, and rapamycin and structural derivatives or functional analogs thereof, such as 40-O-(2-hydroxy)ethyl-rapamycin (known by the trade name of EVEROLIMUS available from

Novartis), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

To provide more biological benefits, at least one additional biologically active agent can be optionally incorporated into the outermost layer of the stent coating, for example, by 5 conjugating the biologically active agent to the biologically beneficial polymer that is present in the outermost layer. As a result of conjugation, an adduct of the biologically active agent and the biologically beneficial polymer can be formed. The adduct can be then used for making the outermost layer. For example, the adduct can be dissolved in a suitable solvent, or a mixture of solvents, and the resulting solution of the adduct can be applied on the stent as described above.

10 The additional biologically active agent can include any substance capable of exerting a therapeutic or prophylactic effect in the practice of the present invention. Some examples of drugs that can be used for conjugation with PEG or POLYACTIVE block-copolymer include peptides such as polyarginine (e.g., R7) or c-RGD, antisense agents (e.g., Rensten-NG), rapamycin and structural derivatives or functional analogs thereof, such as EVEROLIMUS, 40-O- 15 (3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, and molecules that are sources of nitrogen oxide (NO) such as diazenium diolates.


One method of conjugating an additional biologically active agent to PEG or POLYACTIVE block-copolymer is by reactions of polymer-analogous transformation of PEG or POLYACTIVE block-copolymer, utilizing the reactive functional groups of PEG or the 20 copolymer. For instance, the free hydroxyls of PEG or the PEG blocks can be used for conjugating. An example of an additional biologically active agent that can be conjugated to PEG or POLYACTIVE block-copolymer is a diazenium diolate type nitric oxide donor and the process of conjugating can be carried out as described below.

25 Diazenium diolate type nitric oxide donors are adducts of nitric oxide with nucleophilic amines. Diazenium diolates, also known as “NONOates,” are highly biologically compatible, and in slightly acidic medium they spontaneously release NO. One example of diazenium diolate that can be used is spermine diazenium diolate (SDD).


30 SDD, also known by its chemical name as 1,3-propanediamine, N-{4-[1-(3-aminopropyl)-2-hydroxy-2-nitrosohydrazino] butyl}-diazen-1-i um-1,2-diolate, is aliphatic NONOate having the formula $\text{NH}_2-(\text{CH}_2)_3-\text{N}[\text{N}^+(\text{O})-(\text{N}^-\text{OH})]-(\text{CH}_2)_4-\text{NH}-(\text{CH}_2)_3-\text{NH}_2$. SDD is available from Molecular Probes, Inc. of Eugene, Oregon. Alternatively, other diazenium diolate-type NO donors can be used. Some examples of the alternative diazenium diolate-type NO donors that can be conjugated to the PEG blocks of PEG-PCL-PEG include 1-{N-methyl-N-[6-(N-

5 methylammonio)hexyl]amino} diazen-1-iium-1,2-diolate having the formula $\text{CH}_3-\text{N}^+\text{H}_2-(\text{CH}_2)_6-$
 N(CH₃)-N⁺(O)=N-O⁻ (MAHMA-NO), and Z-1-[N-(2-aminoethyl)-N-(2-
 ammonioethyl)amino]diazen-1-iium-1,2-diolate having the formula
 10 O-N⁺[N(CH₂CH₂NH₂)CH₂CH₂N⁺H₃]=N-O⁻ (DETA-NO). MAHMA-NO and DETA-NO can be
 obtained from Cayman Chemical Co. of Ann Arbor, Michigan.


15 To conjugate SDD to PEG, PEG can be preliminarily derivatized by tosylation (treatment with tosyl chloride), or alternatively by tresylation (by reacting with tresyl chloride). Tosyl chloride is a derivative of toluene, para-toluenesulfonyl chloride having the formula CH₃-C₆H₄-SO₂Cl (TsCl). The process of tosylation includes an attack on the terminal hydroxyl of the PEG
 molecule and can be illustrated by reaction (VI):



15 Alternatively, tresyl chloride (2,2,2-trifluoroethanesulphonyl chloride) can be used to derivatize PEG. The process of tresylation also includes an attack on the terminal hydroxyl of the PEG molecule and can be illustrated by reaction (VII):



20 Next, tosylated or tresylated PEG can be modified by conjugating SDD. Due to the presence of two primary and one secondary amino groups, SDD is readily conjugated to the tosylated or tresylated PEG- via alkylation of the amino groups. One possible process of conjugating can be shown for tosylated PEG as reaction (VIII):



30 Since POLYACTIVE block-copolymer includes two terminal PEG blocks (as can be seen from the formula PEG-PBT-PEG), the process similar to those described by reactions (VI-VIII) can be also used to modify POLYACTIVE block-copolymer by conjugating SDD to one or both PEG blocks

that are present in the POLYACTIVE block-copolymer. SDD can be also conjugated to PBT-PEG-PBT block-copolymer, using terminal carboxyl groups of that are present in the PBT blocks of PBT-PEG-PBT copolymer. One or both PBT blocks of PBT-PEG-PBT block-copolymer can be used for conjugating SDD. Those having ordinary skill in the art can determine under which conditions the 5 two-step process of conjugating SDD to PEG, POLYACTIVE, or PBT-PEG-PBT block-copolymer described above can be carried out.

The resulting polymeric adducts can be described schematically as:

- (a) Dz-PEG-PBT-PEG (one PEG block of POLYACTIVE is modified);
- (b) Dz-PEG-PBT-PEG-Dz (two PEG blocks of POLYACTIVE are modified);
- 10 (c) PEG-Dz (PEG is modified);
- (d) Dz-PBT-PEG -PBT (one PBT block of PBT-PEG -PBT copolymer is modified); and
- (e) Dz-PBT-PEG-PB -Dz (two PBT blocks of PBT-PEG-PBT copolymer are modified),

where Dz is a fragment derived from SDD.

The coatings and methods of the present invention have been described with reference to a 15 stent, such as a balloon expandable or self-expandable stent. The use of the coating is not limited to stents, however, and the coating can also be used with a variety of other medical devices. Examples of the implantable medical device, that can be used in conjunction with the embodiments of this invention include stent-grafts, grafts (e.g., aortic grafts), artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, axius coronary shunts and endocardial leads (e.g., FINELINE and 20 ENDOTAK, available from Guidant Corporation). The underlying structure of the device can be of virtually any design. The device can be made of a metallic material or an alloy such as, but not limited to, cobalt-chromium alloys (e.g., ELGILOY), stainless steel (316L), "MP35N," "MP20N," ELASTINITE (Nitinol), tantalum, tantalum-based alloys, nickel-titanium alloy, platinum, platinum-based alloys such as, e.g., platinum-iridium alloy, iridium, gold, magnesium, titanium, titanium-based 25 alloys, zirconium-based alloys, or combinations thereof. Devices made from bioabsorbable or biostable polymers can also be used with the embodiments of the present invention.

"MP35N" and "MP20N" are trade names for alloys of cobalt, nickel, chromium and molybdenum available from Standard Press Steel Co. of Jenkintown, Pennsylvania. "MP35N"

consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum. "MP20N" consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum.

3. Examples

5 The following examples are provided to further illustrate embodiments of the present invention.

Example 1

A first composition was prepared by mixing the following components:

(a) about 2.0 mass % poly(butyl methacrylate) (PBMA); and

10 (b) the balance, a solvent blend comprising acetone and cyclohexanone in a mass ratio of about 7:3.

The first composition was applied onto the surface of a bare 18 mm VISION stent (available from Guidant Corporation) by spraying and dried to form a primer layer. A spray coater was used having a 0.014 fan nozzle maintained at about 60°C with a feed pressure of about 0.2 atm (about 3 psi) and an atomization pressure of about 1.3 atm (about 20 psi). The primer 15 was dried and baked at about 50°C for about 1 hour, yielding a dry primer layer containing about 80 µg of PBMA.

A second composition was prepared by mixing the following components:

(a) about 2.0 mass % SOLEF 21508;

(b) about 1.0 mass % EVEROLIMUS; and

20 (c) the balance, a solvent blend comprising acetone and cyclohexanone in a mass ratio of about 7:3.

The second composition contained about 300 µg SOLEF and about 200 µg EVEROLIMUS. The second composition was applied onto the dried primer layer to form the reservoir layer, using the same spraying technique and equipment used for applying the primer 25 layer, followed by drying and baking at about 50°C for about 2 hours.

A third composition was prepared by mixing the following components:

(a) about 2.0 mass % POLYACTIVE containing about 45 molar % PBT units and about 55 molar % PEG units; the molecular weight of the PEG units was about 300 Daltons;

(b) the balance, a solvent blend, the blend comprising 1,1,2-trichloroethane and chloroform in a mass ratio of about 4:1.

5 The third composition was applied onto the dried reservoir layer to form a topcoat layer, using the same spraying technique and equipment used for applying the primer layer and the reservoir layer, followed by drying and baking at about 50°C for about 2 hours, yielding a dry topcoat layer containing about 250 µg of POLYACTIVE.

The coated stent was subjected to simulated testing according to the following procedure.

10 The stent was installed on a catheter and guided through a tortuous path and then deployed in a poly(vinyl alcohol) lesion having approximate size of about 3 by 10 millimeters. The tortuous path and the lesion contained de-ionized water at about 37°C. To deploy the stent, pressure of about 16 atm was applied to the balloon for about 1 minute, followed by deflating of the balloon and retraction of the catheter. After the catheter was retracted, de-ionized water was pumped
15 through the tortuous path and the lesion for about 1 hour at a rate of about 50 milliliters per minute. Water was maintained at about 37°C.

Overall views of the coated stent which underwent the simulated in-vitro testing are shown by the microphotographs on FIGs. 1A, 1B, 1C, 2A, 2B and 2C. After the simulated use test, the quality of the stents coatings was good. No damage of the coatings on the outer surface area
20 (FIGs. 1A, 1B, and 1C) or inner surface area (FIGs. 2A, 2B, and 2C) was observed.

Example 2

The primer layer can be formed on an 18 mm VISION stent as described in Example 1.

A first composition can be prepared by mixing the following components:

25 (a) between about 0.5 mass % and about 2.5 mass %, for example, about 2.0 mass % EVEROLIMUS; and

(b) the balance, a solvent blend comprising acetone and xylene in a mass ratio of about 2:3.

The first composition can contain about 300 µg EVEROLIMUS. The composition can be applied onto the dried primer layer to form the reservoir layer, using the same spraying technique

and equipment used for applying the primer layer, followed by drying and baking at about 50°C for about 1 hour.

A second composition can be prepared by mixing the following components:

- (a) between about 1.0 mass % and about 15 mass %, for example, about 2.0 mass %
5 SOLEF 21508; and
- (b) the balance, a solvent blend comprising acetone and cyclohexanone in a mass ratio of about 7:3.

The second composition can be applied onto the dried reservoir layer to form the topcoat layer, using the same spraying technique and equipment used for applying the primer layer,
10 followed by drying and baking at about 50°C for about 2 hours, yielding a dry topcoat layer containing about 300 µg of SOLEF.

A third composition can be prepared by mixing the following components:

- (a) between about 1.0 mass % and about 15 mass %, for example, about 2.0 mass % poly(ester amide); and
15
- (b) the balance, ethanol.

The third composition can be applied over the dried topcoat layer using techniques described above, followed by drying and baking at about 50°C for about 2 hours, yielding a dry finishing coat layer containing about 150 µg of poly(ester amide).

While particular embodiments of the present invention have been shown and described, it
20 will be obvious to those skilled in the art that changes and modifications can be made without departing from this invention in its broader aspects. Therefore, the appended claims are to encompass within their scope all such changes and modifications as fall within the true spirit and scope of this invention.

CLAIMS

WHAT IS CLAIMED IS:

1. A medical article, comprising a coating disposed on at least a portion of an implantable medical device, the coating comprising:
 - 5 (a) a fluorinated polymer; and
 - (b) a biologically beneficial polymer.
2. The medical article of Claim 1, wherein the implantable medical device is a stent.
3. The medical article of Claim 1, wherein the fluorinated polymer includes:
 - (a) products of polymerization of fluorinated olefins or mixtures thereof;
 - 10 (b) products of polymerization of fluorinated cyclic esters;
 - (c) fluorine-containing cyclic polymers having a main chain with an asymmetrical cyclic structure; or
 - (d) copolymers of perfluoro-2,2-dimethyl-1,3-dioxole with perfluoroolefins or with perfluoro(alkyl vinyl) ethers.
- 15 4. The medical article of Claim 3, wherein the products of polymerization of fluorinated olefins are selected from a group consisting of poly(vinylidene fluoride-co-hexafluoropropene), poly(tetrafluoroethylene), fluorinated poly(ethylene-co-propylene), poly(hexafluoropropene), poly(chlorotrifluoroethylene), poly(vinylidene fluoride), poly(vinylidene fluoride-co-tetrafluoroethylene), poly(tetrafluoroethylene-co-hexafluoropropene),
20 poly(tetrafluoroethylene-co-vinyl alcohol), poly(tetrafluoroethylene-co-vinyl acetate), poly(tetrafluoroethylene-co-propene), poly(hexafluoropropene-co-vinyl alcohol), poly(ethylene-co-tetrafluoroethylene), poly(ethylene-co-hexafluoropropene), and poly(vinylidene fluoride-co-chlorotrifluoroethylene).
- 25 5. The medical article of Claim 3, wherein the products of polymerization of fluorinated cyclic esters is poly(perhalo-2,2-dimethyl-1,3-dioxole-co-perfluoro-2-methylene-methyl-1,3-dioxolane).


6. The medical article of Claim 3, wherein the fluorine-containing cyclic polymers are selected from a group of polymers with repeating units of cyclically polymerized perfluorallyl vinyl ether and/or perfluorobut enyl vinyl ether.

7. The medical article of Claim 1, wherein the biologically beneficial polymer is selected from a group consisting of poly(ethylene-glycol), poly(ethylene-glycol)-block-poly(butylene terephthalate)-block-poly(ethylene-glycol), poly(butylene terephthalate)-block-poly(ethylene-glycol)-block poly(butylene terephthalate), hyaluronic acid, derivatives of hyaluronic acid, poly(ethylene oxide-co-propylene oxide), phosphoryl choline, polyaspirin, and poly(ester amides).

10 8. The medical article of Claim 7, wherein poly(ester amides) include polymers having at least one ester bond and at least one amide bond.


9. The medical article of Claim 7, wherein poly(ester amides) include polymers having a general formula $-\text{[M-P]}_m-\text{[M-Q]}_n-$, wherein M is a moiety represented by the structure

15




P is a moiety selected from a group (P1)-(P4) consisting of:



20




25




30



Q is a moiety selected from a group (Q1)-(Q4) consisting of:



5



10 —O—Z—O— (Q3), and

—NH—Z—NH— (Q4);

wherein:

15 R_1 is selected from a group consisting of a straight chained or branched aliphatic alkylene group C_rH_{2r} , wherein r is an integer having the value between 2 and 12, and an aromatic group;

R_2 is selected from a group consisting of hydrogen, methyl, *iso*-propyl, *sec*-butyl, *iso*-butyl, and benzyl;

R_3 is selected from a group consisting of methylene, methylmethylene, *n*-propylene, *iso*-20 propylene, ethylmethylene, straight chained or branched butylene, and *n*-amylene;

X is a straight chained or branched aliphatic alkylene group C_xH_{2x} , wherein x is an integer between 2 and 12;

Y is a straight chained or branched aliphatic alkylene group C_yH_{2y} , wherein y is 2, 4, or 5;


Z is a biologically beneficial moiety derived from PEG, poly(propylene glycol),

25 hyaluronic acid or derivatives thereof, poly(2-hydroxyethyl methacrylate) or cellulosics; and

m and n are integers.

10. The medical article of Claim 7, wherein poly(ester amide) is a product of reaction between a diol-diamine and a dicarboxylic acid.

11. The medical article of Claim 7, wherein poly(ester amide) is a polymer that
30 includes a unit having the formula



wherein R is selected from a group consisting of hydrogen; methyl, *iso*-propyl, *sec*-butyl, *iso*-butyl, and benzyl; x is an integer having a value between 2 and 12; and y is an integer having a value between 1 and 12.

12. The medical article of Claim 1, wherein the biologically beneficial polymer is a
5 polymeric adduct comprising a biologically active agent.

13. The medical article of Claim 12, wherein the biologically active agent comprises peptides, antisense agents, rapamycin and structural derivatives or functional analogs thereof, and molecules that are sources of nitrogen oxide.

14. A method for fabricating a medical article, comprising:
10 (a) depositing a fluorinated polymer on at least a portion of an implantable medical device to form a first polymeric layer; and

(b) depositing a biologically beneficial polymer on at least a portion of the first polymeric layer to form a second polymeric layer.

15. The method of Claim 14, wherein the implantable medical device is a stent.

16. The method of Claim 14, wherein the fluorinated polymer includes:
15 (a) products of polymerization of fluorinated olefins or mixtures thereof;
(b) products of polymerization of fluorinated cyclic esters;
(c) fluorine-containing cyclic polymers having a main chain with an asymmetrical cyclic structure; or
20 (d) copolymers of perfluoro-2,2-dimethyl-1,3-dioxole with perfluoroolefins or with perfluoro(alkyl vinyl) ethers.

17. The method of Claim 16, wherein the products of polymerization of fluorinated olefins are selected from a group consisting of poly(vinylidene fluoride-co-hexafluoropropene), poly(tetrafluoroethylene), fluorinated poly(ethylene-co-propylene), poly(hexafluoropropene),
25 poly(chlorotrifluoroethylene), poly(vinylidene fluoride), poly(vinylidene fluoride-co-tetrafluoroethylene), poly(tetrafluoroethylene-co-hexafluoropropene), poly(tetrafluoroethylene-co-vinyl alcohol), poly(tetrafluoroethylene-co-vinyl acetate), poly(tetrafluoroethylene-co-propene), poly(hexafluoropropene-co-vinyl alcohol), poly(ethylene-co-tetrafluoroethylene), poly(ethylene-co-hexafluoropropene), and poly(vinylidene fluoride-co-chlorotrifluoroethylene).


18. The method of Claim 16, wherein the products of polymerization of fluorinated cyclic esters is poly(perhalo-2,2-dimethyl-1,3-dioxole-co-perfluoro-2-methylene-methyl-1,3-dioxolane).

19. The method of Claim 16, wherein the fluorine-containing cyclic polymers are selected from a group of polymers with repeating units of cyclically polymerized perfluorallyl vinyl ether and/or perfluorobutenyl vinyl ether.




20. The method of Claim 14, wherein the biologically beneficial polymer is selected from a group consisting of poly(ethylene-glycol), poly(ethylene-glycol)-block-poly(butyleneterephthalate)-block-poly(ethylene-glycol), poly(butyleneterephthalate)-block-poly(ethylene-glycol)-block poly(butyleneterephthalate), hyaluronic acid, derivatives of hyaluronic acid, poly(ethylene oxide-co-propylene oxide), phosphoryl choline, polyaspirin, and poly(ester amides).

21. The method of Claim 20, wherein poly(ester amides) include polymers having both at least one ester bond and at least one amide bond.


22. The method of Claim 20, wherein poly(ester amides) include polymers having a general formula $-\text{[M-P]}_m-\text{[M-Q]}_n-$, herein M is a moiety represented by the structure




20 P is a moiety selected from a group (P1) – (P4), consisting of:



Q is a moiety selected from a group (Q1) -- (Q4), consisting of:



5



10

—O—Z—O— (Q3), and

—NH—Z—NH— (Q4);

wherein:

15 R₁ is selected from a group consisting of a straight chained or branched aliphatic alkylene group C_rH_{2r}, wherein r is an integer having the value between 2 and 12, and an aromatic group;

R_2 is selected from a group consisting of hydrogen, methyl, *iso*-propyl, *sec*-butyl, *iso*-butyl, and benzyl;

R_3 is selected from a group consisting of methylene, methylmethylen, *n*-propylene, *iso*-
20 propylene, ethylmethylen, straight chained or branched butylene, and *n*-amylene;

X is a straight chained or branched aliphatic alkylene group C_xH_{2x} , wherein x is an integer between 2 and 12;


Y is a straight chained or branched aliphatic alkylene group C_yH_{2y} , wherein y is 2, 4, or 5;

Z is a biologically beneficial moiety derived from PEG, poly(propylene glycol),
25 hyaluronic acid or derivatives thereof, poly(2-hydroxyethyl methacrylate) or cellulosics; and

m and n are integers.

23. The method of Claim 20, wherein poly(ester amide) is a product of reaction between a diol-diamine and a dicarboxylic acid.

24. The method of Claim 20, wherein poly(ester amide) is a polymer including a unit
30 having the formula



wherein R is selected from a group consisting of hydrogen; methyl, *iso*-propyl, *sec*-butyl, *iso*-butyl, and benzyl; x is an integer having a value between 2 and 12; and y is an integer having a value between 1 and 12.

25. The method of Claim 14, additionally including conjugating a biologically active
5 agent to the biologically beneficial polymer.

26. The method of Claim 25, wherein the biologically active agent comprises peptides, antisense agents, rapamycin and structural derivatives or functional analogs thereof, and molecules that are sources of nitrogen oxide.

1/2




FIG. 1A




FIG. 1B




FIG. 1C

2/2




FIG. 2A



FIG. 2B



FIG. 2C

INTERNATIONAL SEARCH REPORT

PCT/US2004/038135

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61L31/10 A61L31/16 A61L27/34 A61L27/54

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61L C08L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	<p>WO 03/022323 A (ADVANCED CARDIOVASCULAR SYSTEMS, INC) 20 March 2003 (2003-03-20)</p> <p>page 8, paragraph 20</p> <p>page 9, paragraphs 21,22</p> <p>page 16, paragraph 30</p> <p>page 15, line 3</p> <p>-----</p> <p>WO 02/26281 A (CORDIS CORPORATION) 4 April 2002 (2002-04-04)</p> <p>page 24, line 23 – page 25, line 15</p> <p>page 26, line 1 – page 27, line 22</p> <p>example 2</p> <p>figures 8,9</p> <p>-----</p> <p>-/-</p>	1-4,7, 12-17, 20,25,26
X		1-4, 12-17, 25,26

 Further documents are listed in the continuation of box C Patent family members are listed in annex

* Special categories of cited documents

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

& document member of the same patent family

Date of the actual completion of the international search

10 May 2005

Date of mailing of the international search report

20/05/2005

Name and mailing address of the ISA

European Patent Office, P B 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel (+31-70) 340-2040, Tx 31 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

Staber, B

INTERNATIONAL SEARCH REPORT

PCT/US2004/038135

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
E	WO 2004/101018 A1 (ADVANCED CARDIOVASCULAR SYSTEMS, INC) 25 November 2004 (2004-11-25) page 10, line 19 example 6 -----	1-4,7, 12,13
E	WO 2005/011770 A (ADVANCED CARDIOVASCULAR SYSTEMS, INC; HOSSAINY, SYED, F. A; MICHAL, EU) 10 February 2005 (2005-02-10) page 8, line 5 - line 18 page 10, line 15 - line 16 page 12, line 28 - line 34 -----	1-4,7, 12,13
A	FULTON J L ET AL: "Thin fluoropolymer films and nanoparticle coatings from the rapid expansion of supercritical carbon dioxide solutions with electrostatic collection" POLYMER, ELSEVIER SCIENCE PUBLISHERS B.V., GB, vol. 44, no. 13, June 2003 (2003-06), pages 3627-3632, XP004428304 ISSN: 0032-3861 figure 4 -----	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

PCT/US2004/038135

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 03022323	A	20-03-2003	WO	03022323 A1		20-03-2003
WO 0226281	A	04-04-2002	US	2001029351 A1	11-10-2001	
			US	2002143386 A1	03-10-2002	
			US	2002165608 A1	07-11-2002	
			AU	1129902 A	08-04-2002	
			AU	1132102 A	08-04-2002	
			AU	7730201 A	11-04-2002	
			AU	9316101 A	08-04-2002	
			AU	9486901 A	08-04-2002	
			CA	2357881 A1	29-03-2002	
			CA	2424029 A1	04-04-2002	
			CA	2424038 A1	04-04-2002	
			CA	2424049 A1	04-04-2002	
			CA	2425753 A1	04-04-2002	
			CN	1477980 A	25-02-2004	
			EP	1192957 A2	03-04-2002	
			EP	1335761 A1	20-08-2003	
			EP	1322235 A1	02-07-2003	
			EP	1322351 A1	02-07-2003	
			EP	1322342 A1	02-07-2003	
			JP	2002238994 A	27-08-2002	
			JP	2004521668 T	22-07-2004	
			JP	2004524868 T	19-08-2004	
			JP	2004518458 T	24-06-2004	
			WO	0226280 A1	04-04-2002	
			WO	0226139 A1	04-04-2002	
			WO	0226281 A1	04-04-2002	
			WO	0226271 A1	04-04-2002	
			US	2004102758 A1	27-05-2004	
			US	2004197372 A1	07-10-2004	
			US	2002094440 A1	18-07-2002	
			US	2002111590 A1	15-08-2002	
			US	2002133183 A1	19-09-2002	
			US	2002051730 A1	02-05-2002	
			CA	2408754 A1	22-11-2001	
			JP	2004504078 T	12-02-2004	
			WO	0187375 A1	22-11-2001	
			US	2005004663 A1	06-01-2005	
			CA	2442327 A1	10-10-2002	
			EP	1372752 A1	02-01-2004	
			JP	2004524916 T	19-08-2004	
			WO	02078762 A1	10-10-2002	
			US	2002193867 A1	19-12-2002	
			CA	2450962 A1	03-01-2003	
			EP	1406682 A1	14-04-2004	
			JP	2004531331 T	14-10-2004	
			WO	03000308 A1	03-01-2003	
WO 2004101018	A1	25-11-2004	US	2004224001 A1	11-11-2004	
WO 2005011770	A	10-02-2005	US	2005025799 A1	03-02-2005	
			WO	2005011770 A2	10-02-2005	